A new high-performance liquid chromatography method determines low production of 9-β-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 499-504

  Yamauchi, Takahiro ^a   Nishi, Rie ^a   Kitazumi, Kazuhiro ^b   Nakano, Tsuyoshi ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Development and Medical Affairs Division   (Japan)

Author keywords

9 D arabinofuranosylguanine; Adult T cell leukemia; Ara G triphosphate; Isocratic HPLC; Nelarabine

Indexed keywords

9 BETA DEXTRO ARABINOFURANOSYLGUANINE TRIPHOSPHATE; GUANINE ARABINOSIDE; GUANOSINE TRIPHOSPHATE; NELARABINE; UNCLASSIFIED DRUG;

ANION EXCHANGE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; ARABINONUCLEOTIDES; BIOLOGICAL MARKERS; CELL PROLIFERATION; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GUANOSINE TRIPHOSPHATE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PRODRUGS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 76649117799     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000661     Document Type: Article

References (20)

1. Cohen A, Lee JW and Gelfand EW: Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61: 660-666, 1983.
2. Hebert ME, Greenberg ML, Chaffee S, Gravatt L, Hershfield MS, Elion GB and Kurtzberg J: Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine. Transplantation 52: 634-640, 1991.
3. Cohen MH, Johnson JR, Massie T, et al: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/ lymphoma. Clin Cancer Res 12: 5329-5335, 2006.
4. Gandhi V, Plunkett W, Rodriguez CO Jr, et al: Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16: 3607-3615, 1998.
5. Gandhi V, Plunkett W, Weller S, et al: Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19: 2142-2152, 2001.
6. Rodriguez CO Jr and Gandhi V: Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res 59: 4937-4943, 1999.
7. Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S and Gandhi V: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62: 3100-3105, 2002.
8. Rodriguez CO Jr, Stellrecht CM and Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102: 1842-1848, 2003.
9. Gandhi V, Mineishi S, Huang P, et al: Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol 22 (4 Suppl 11): 61-67, 1995.
10. 4-behenoyl- 1-β-D-arabino furanosylcytosine therapy for acute myelogenous leukemia. Cancer Sci 92: 975-982, 2001.
11. Yamamoto S, Yamauchi T, Kawai Y, et al: Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol 85: 108-115, 2007.
12. Rodriguez CO Jr, Plunkett W, Paff MT, et al: High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 745: 421-430, 2000.
13. Taylor GP and Matsuoka M: Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24: 6047-6057, 2005.
14. Yasunaga J and Matsuoka M: Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 14: 133-140, 2007.
15. Murata K and Yamada Y: The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol 26: 249-268, 2007.
16. Yamauchi T and Ueda T: Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 799: 81-86, 2004.
17. Yamauchi T, Ueda T and Nakamura T: A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Cancer Res 56: 1800-1804, 1996.
18. Yamauchi T, Ogawa M and Ueda T: Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. Mol Pharmacol 74: 82-91, 2008.
19. Gandhi V, Tam C, O'Brien S, et al: Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 26: 1098-1105, 2008.
20. Yamada Y, Tomonaga M, Fukuda H, et al: A new G-CSFsupported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001.